COVID-19 Pandemic Boosts Antimicrobial Technology Innovation, Finds IDTechEx finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases , which amended. | March 31, 2023
Share:
Arrhythmia, a condition that causes the heart to beat with an irregular or abnormal rhythm, is the fourth leading disease in the United States. Untreated or undiagnosed, arrhythmias can increase the risk of severe health complications including stroke or even death.
Medtech company BioSig Technologies (NASDAQ: BSGM) has developed the PURE EP System, a technology that aims to improve the visuals of cardiac signals for surgeons that treat irregular heartbeats. The company hopes this will encourage more arrhythmia patients to elect for surgical treatment a therapy option that is increasingly proving more effective than pharmaceutical alternatives.
With major players in the space like Johnson & Johnson (NYSE: JNJ), Medtronic (NYSE: MDT) and Abbott (NYSE: ABT) grabbing the attention of investors, let’s look at why and how BioSig is claiming a name for itself in the industry.